Mezagitamab, CAS 2227490-52-8

Product Description: Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP)[1][2][3].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Abadier M, et al. Mezagitamab induces immunomodulatory effect in patients with relapsed/refractory multiple myeloma (RRMM)[J]. Blood, 2020, 136: 9./[2]Jadoon Y, et al. Immunotherapy in multiple myeloma. Cancer Treat Res Commun. 2021;29:100468. /[3]Kuter DJ. Novel therapies for immune thrombocytopenia. Br J Haematol. 2022 Mar;196(6):1311-1328.

CAS Number: 2227490-52-8

Molecular Weight: N/A

Compound Purity: 95.00

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: CD38

• Artikelnummer: MEXHY-P99730-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99730-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated